ReShape Lifesciences Inc
NASDAQ:RSLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ReShape Lifesciences Inc
Selling, General & Administrative
ReShape Lifesciences Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Selling, General & Administrative
-$9.2m
|
CAGR 3-Years
38%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Selling, General & Administrative
-$7.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Selling, General & Administrative
-$2.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-10%
|
|
|
Stryker Corp
NYSE:SYK
|
Selling, General & Administrative
-$8.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Selling, General & Administrative
-$12.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Selling, General & Administrative
-$2.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
ReShape Lifesciences Inc
Glance View
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The firm's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.
See Also
What is ReShape Lifesciences Inc's Selling, General & Administrative?
Selling, General & Administrative
-9.2m
USD
Based on the financial report for Mar 31, 2025, ReShape Lifesciences Inc's Selling, General & Administrative amounts to -9.2m USD.
What is ReShape Lifesciences Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
9%
Over the last year, the Selling, General & Administrative growth was 36%. The average annual Selling, General & Administrative growth rates for ReShape Lifesciences Inc have been 38% over the past three years , 9% over the past five years .
